Cortexyme Says FDA Places Partial Clinical Hold On Atuzaginstat

(RTTNews) – Cortexyme Inc. (CRTX), in an update on development program for Atuzaginstat in Alzheimer’s Disease, said that the U.S. Food and Drug Administration has placed a partial clinical hold on atuzaginstat (COR388) that will impact the open-label extension or OLE phase of thRead MoreMarketsMarkets Feed